BrainAurora Medical Technology Ltd. announced that its wholly-owned subsidiary, Beijing Zhijingling Technology Co., Ltd., has become a key partner in a Major National Science and Technology Project focused on the prevention and treatment of cancer, cardiovascular and cerebrovascular, respiratory, and metabolic diseases. The company is also involved in the establishment of the Beijing Key Laboratory for Digital Healthcare for Cognitive Impairment, in collaboration with Xuanwu Hospital. This partnership underscores the recognition of BrainAurora’s research and technological capabilities at both national and municipal levels, and is expected to strengthen its position in the medical and digital therapeutics sectors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainaurora Medical Technology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11962815), on December 22, 2025, and is solely responsible for the information contained therein.
Comments